🔍

Emcure Pharmaceuticals Limited (EMCURE)

₹1,820.60 -0.84% last close, 16 Oct

📊 NSE: EMCURE 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 12 Oct 2026 📝 Analysis written: 13 Dec 2025

Q2 FY27 results

📅 Next results: 03 Nov 2026 (board meeting)

Emcure Pharmaceuticals Limited's board meets on 3 Nov 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Emcure Pharmaceuticals' revenue was ₹2,580 Cr (+22.8% year on year, +4.5% on the previous quarter), and net profit ₹292 Cr (+36.0% year on year); the operating margin was 20.6%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹2,580	+22.8%	+4.5%
Operating profit	₹532	+27.7%	+10.9%
Net profit	₹292	+36.0%	+19.9%
EPS (₹)	15.50	+41.9%	+20.7%
Operating margin	20.6%	—	—

Full quarterly financials → Results calendar →

EMCURE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 53.54% of the EMCURE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 53.11%. That is close to its usual level. Volume was 0.2 times its average, well below normal. It closed at a price band (circuit) on 1 session in about the last 20.

53.54%Delivery, 16 Oct

53.11%Own 20-session average

0.2×Volume vs its average

₹1,820.60NSE close · -0.84%

Delivery in the last 5 sessions: 50.6% · 45.2% · 77.4% · 66.1% · 53.5%

Delivery across the market →Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Emcure Approves Merger of WOS Zuventus and Emcutix to Streamline Corporate Structure

🟡 NEUTRAL ⭐ 6/10

M&A 📅 12 Oct 2026, 10:33 AM

Emcure Pharmaceuticals has approved a draft Composite Scheme of Amalgamation to merge two wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, into the parent entity. Zuventus Healthcare reported a turnover of ₹1,040.58 Cr and net worth of ₹871.46 Cr for FY 2025-26, representing about 11% of Emcure's TTM consolidated revenue of ₹9,684 Cr. Emcutix reported a FY26 turnover of ₹29.37 Cr and negative net worth of ₹(13.07) Cr. Because both entities are 100% owned, no cash consideration will be paid and no new shares will be issued, resulting in zero equity dilution.

Merger of wholly owned subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals into parent Emcure Pharmaceuticals
Zuventus Healthcare recorded FY26 turnover of ₹1,040.58 Cr and net worth of ₹871.46 Cr
Emcutix Biopharmaceuticals recorded FY26 turnover of ₹29.37 Cr and net worth of ₹(13.07) Cr
No shares issued and zero cash consideration payable, causing no change in the shareholding pattern

💡 Track the regulatory timeline including approvals from the NCLT Mumbai bench, statutory bodies, and creditors over the next 6-12 months.

Emcure Faces ₹57.74 Cr Income Tax Penalty Orders for FY15–FY21; Plans Appeal

🔵 WATCH ⭐ 5/10

LEGAL 📅 02 Oct 2026, 09:31 PM

Emcure Pharmaceuticals has received penalty orders totaling ₹57.74 crore from the Income-tax Department (Deputy Commissioner of Income tax, Central Circle 2(1)- Pune). The penalties pertain to FY 2014-15 through FY 2020-21 (AY 2015-16 to AY 2021-22), stemming from proceedings initiated on December 27, 2023. The penalty amount represents approximately 5.7% of Emcure's TTM PAT of ₹1,019 crore and about 0.6% of TTM revenue of ₹9,684 crore. The company stated it is evaluating legal remedies, including filing an appeal before the Appellate Authority.

Received orders imposing an aggregate penalty of ₹57,73,96,732 from the Income-tax Department
Penalty covers 7 assessment years: AY 2015-16 to AY 2021-22 (FY 2014-15 to FY 2020-21)
Litigation was initially initiated on December 27, 2023
Company is in the process of evaluating legal remedies, including filing an appeal

💡 Track the filing of appeals before the Appellate Authority and monitor whether any cash deposit or stay order is required during the appellate process.

Emcure Releases Investor Presentation Highlighting 16.6% FY26 Revenue Growth

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Sep 2026, 04:41 PM

Emcure Pharmaceuticals published its comprehensive corporate investor presentation detailing historical performance through FY26 and Q1 FY27. For FY26, the company reported revenue of Rs 9,203.5 Cr (up 16.6% YoY) and PAT of Rs 941.3 Cr (up 33.1% YoY), driven by strong international expansion (up 22.2%) and domestic growth (up 10.0%). For Q1 FY27, revenue reached Rs 2,580.4 Cr (up 22.8% YoY) with PAT rising 36.2% YoY to Rs 292.5 Cr. The presentation also details strategic updates including the full buyout of Zuventus for Rs 724.9 Cr.

FY26 Revenue from Operations stood at Rs 9,203.5 Cr, marking a 16.6% YoY expansion
FY26 PAT reached Rs 941.3 Cr, reflecting 33.1% YoY growth with margins expanding 120 bps to 10.2%
Q1 FY27 Revenue rose 22.8% YoY to Rs 2,580.4 Cr, while Q1 FY27 PAT increased 36.2% YoY to Rs 292.5 Cr
Net cash outflow of Rs 724.9 Cr incurred in FY26 for acquiring the non-controlling interest in Zuventus Healthcare
Net debt stood at Rs 1,053.8 Cr as of March 31, 2026, with gross debt at Rs 1,204.1 Cr

💡 Track the integration and margin delivery of recent acquisitions (Zuventus and Manx Healthcare) and watch upcoming Q2 FY27 earnings for sustained chronic and international market momentum.

Emcure Pharma Shareholders Approve All Resolutions at 45th AGM, Reappoint Satish Mehta as MD & CEO

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Sep 2026, 06:12 PM

Emcure Pharmaceuticals Limited announced that shareholders approved all resolutions at its 45th Annual General Meeting held on September 21, 2026. Approved items included the declaration of a final dividend of Rs 3.50 per equity share and the reappointment of Mr. Satish Mehta as MD & CEO, which passed with ~94.06% majority (10,004,326 votes against). Reappointments of Ms. Namita Thapar as Director and Dr. Mukund Gurjar as Whole-time Director were also approved. The total votes polled reached approximately 88.99% of total eligible voting shares.

Approval of final dividend of Rs 3.50 per equity share of face value Rs 10
Satish Mehta reappointed as MD & CEO with 94.0593% votes in favor (158,398,409 votes) and 5.9407% against (10,004,326 votes)
Namita Thapar reappointed as Director with 99.8657% votes in favor
Mukund Gurjar reappointed as Whole-time Director with 98.4979% votes in favor
Total voter turnout on key ordinary business was ~88.99% across 168.82 crore polled votes

💡 Track subsequent payout dates for the approved Rs 3.50 dividend and monitor upcoming Q2 FY27 earnings for performance updates.

Emcure Pharma Allots 11,400 Equity Shares Under ESOS 2013

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Sep 2026, 04:34 PM

Emcure Pharmaceuticals Limited has allotted 11,400 equity shares of face value Rs. 10 each following the exercise of vested employee stock options under its ESOS 2013 scheme. Consequently, the company's paid-up equity share capital increased from Rs. 1,89,69,92,470 (18,96,99,247 shares) to Rs. 1,89,71,06,470 (18,97,10,647 shares). The newly issued shares rank pari passu with existing equity shares. Given the negligible volume of shares allotted, the dilution impact is immaterial.

Allotment of 11,400 equity shares of Rs. 10 each pursuant to Emcure ESOS 2013
Issued and paid-up capital expanded from 18,96,99,247 shares to 18,97,10,647 shares
Total paid-up share capital increased from Rs. 1,89,69,92,470 to Rs. 1,89,71,06,470
Allotment approved via Nomination and Remuneration Committee circular resolution on September 11, 2026

💡 Track subsequent quarterly shareholding patterns for incremental employee pool movements; no portfolio action is required as dilution is negligible.

Emcure Dispatches 45th AGM Notice & Annual Report Links to Unregistered Email Holders

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 01 Sep 2026, 04:22 PM

Emcure Pharmaceuticals has dispatched physical communications to shareholders whose email addresses are not registered, providing web-links to the FY25-26 Annual Report and 45th AGM Notice. The 45th AGM is scheduled for September 21, 2026, at 11:00 AM IST via Video Conferencing. Shareholders seeking TDS exemption on the FY26 final dividend must submit documentation by September 14, 2026. The communication also reminds investors holding physical shares to complete mandatory KYC updates.

45th Annual General Meeting scheduled for Monday, September 21, 2026, at 11:00 AM IST via VC/OAVM
Communication dispatched to physical/unregistered email holders based on August 21, 2026 cut-off date
Deadline to submit TDS exemption documents for the FY 2025-26 final dividend is September 14, 2026

💡 Eligible shareholders should submit TDS exemption forms before September 14, 2026, and participate in the AGM on September 21, 2026.

Emcure Pharma Schedules Institutional Investor Meeting on September 4, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Sep 2026, 03:55 PM

Emcure Pharmaceuticals Limited has scheduled a physical meeting with a group of institutional investors on Friday, September 04, 2026, in Pune. The intimation is submitted pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the interaction.

Institutional investor group meeting scheduled for Friday, September 04, 2026
Meeting to be conducted in physical mode in Pune
Company affirmed that no unpublished price sensitive information (UPSI) will be disclosed
Filing made under Regulation 30 of SEBI LODR Regulations, 2015

💡 Track subsequent post-meet disclosures or investor presentations, if any are uploaded to the stock exchanges following the meeting.

CARE Reaffirms Emcure Pharma's Rating at 'CARE AA; Stable/A1+' on Enhanced Rs 2,400 Cr Facilities

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 01 Sep 2026, 03:31 PM

CARE Ratings has reaffirmed its ratings on the bank facilities of Emcure Pharmaceuticals Limited at 'CARE AA; Stable' for long-term and 'CARE A1+' for short-term facilities, covering an enhanced total limit of Rs 2,400 crore (increased from Rs 1,957.50 crore). The rating agency highlighted Emcure's robust FY26 revenue growth of 18% YoY to ~Rs 9,322 crore and PBILDT margin expansion to 20.0% from 18.7% in FY25. Rating strengths include diversified domestic and international scale and strategic in-licensing partnerships, offset by industry regulatory risks and forex exposure.

Total rated bank facilities enhanced by Rs 442.50 Cr to Rs 2,400.00 Cr with ratings reaffirmed at CARE AA; Stable / CARE A1+
Long-term facilities increased to Rs 785.00 Cr (from Rs 557.50 Cr) rated CARE AA; Stable
Consolidated FY26 revenue reached ~Rs 9,322 Cr (up 18% YoY) with PBILDT expanding 26% YoY to ~Rs 1,865 Cr (20.0% margin)
Completed 100% ownership of Gennova Biopharmaceuticals by acquiring remaining 12.05% stake for ~Rs 232 Cr, while divesting mRNA business for ~Rs 140 Cr

💡 Track operating margin sustainability near 20% and working capital debt levels as enhanced limits are utilized to fund portfolio expansions.

Emcure Pharma Issues FY26 Annual Report; 45th AGM Scheduled on Sep 21, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Aug 2026, 09:01 PM

Emcure Pharmaceuticals Limited has issued its Annual Report for FY 2025-26 and scheduled its 45th Annual General Meeting (AGM) for September 21, 2026, via Video Conferencing. Key annual financial figures reported include revenue of INR 92,035 Mn (up 16.6% YoY), EBITDA of INR 17,886 Mn (up 21.8% YoY), and PAT of INR 9,413 Mn (up 33.1% YoY). Remote e-voting begins on September 18, 2026, and concludes on September 20, 2026, with the cut-off date fixed for September 14, 2026.

45th AGM to be held on Monday, September 21, 2026, via Video Conferencing
Cut-off date for AGM e-voting eligibility set for Monday, September 14, 2026
Remote e-voting window open from September 18, 2026 (9:00 AM) to September 20, 2026 (5:00 PM)
FY26 Revenue from operations reported at INR 92,035 Mn (+16.6% YoY) with PAT of INR 9,413 Mn (+33.1% YoY)
R&D spend stood at INR 3,835 Mn (4.2% of sales) and Annual Capex at INR 4,342 Mn in FY26

💡 Track shareholder voting outcomes post-AGM on September 21, 2026, along with management commentary on international expansion and product pipeline execution.

Emcure Pharmaceuticals Allots 19,100 Equity Shares Under ESOS 2013

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Aug 2026, 08:10 PM

Emcure Pharmaceuticals Limited has approved the allotment of 19,100 equity shares of face value Rs 10 each pursuant to the exercise of vested options under the Emcure Employee Stock Option Scheme 2013. Following this allotment, the company's total issued and paid-up equity share capital increased marginally from 18,96,80,147 shares (Rs 1,89,68,01,470) to 18,96,99,247 shares (Rs 1,89,69,92,470). The newly allotted shares rank pari passu with existing shares. The resulting equity dilution is negligible at approximately 0.01%.

Allotted 19,100 equity shares of Rs 10 face value under Emcure ESOS 2013
Paid-up share capital expanded from 18,96,80,147 to 18,96,99,247 equity shares
Total paid-up share capital increased by Rs 1,91,000 to Rs 1,89,69,92,470
Approved via Resolution by Circulation by the Nomination and Remuneration Committee on August 25, 2026

💡 This is a routine administrative share allotment. Investors should focus on upcoming quarterly financial results and core operational execution.

Emcure Q1 FY27: 36.2% PAT Growth to ₹292 Cr and 100% Consolidation of Gennova

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 12 Aug 2026, 06:30 PM

Emcure Pharmaceuticals reported a strong start to FY27 with Q1 revenue growing 22.8% YoY to ₹2,580 crore. Net profit (PAT) surged 36.2% YoY to ₹292 crore, driven by 19.7% EBITDA margins and strong performance in the India business (+10.2% YoY). The company achieved a simplified group structure by acquiring the remaining 12.05% stake in its biotech arm, Gennova, making it a 100% subsidiary. Management also announced a leadership transition with Satish Mehta becoming Chairman and Samit Mehta appointed as COO.

Revenue for Q1 FY27 grew 22.8% YoY to ₹2,580 crore, supported by broad-based growth across geographies.
Profit After Tax (PAT) increased significantly by 36.2% YoY to ₹292 crore.
Acquired the remaining 12.05% minority stake in Gennova, making it a 100% owned subsidiary.
India business returned to double-digit growth, rising 10.2% YoY to ₹1,095 crore.
EBITDA margins expanded by 50 basis points YoY to 19.7%, with EBITDA reaching ₹508 crore.

💡 Monitor the execution of the 'acceleration' phase in the Zuventus business and the progress of the Sanofi in-licensing portfolio. Investors should also track the timeline for the semaglutide launch in Canada, which is currently dependent on supply from partner Dr. Reddy's.

USFDA closes Sanand facility inspection with VAI status; inspection stands closed

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 08 Aug 2026, 10:18 AM

Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the USFDA for its formulations facility in Sanand, Gujarat. The inspection, which took place from May 6 to May 15, 2026, has been classified as Voluntary Action Indicated (VAI). This classification indicates that while some objectionable conditions were observed, the USFDA is not recommending any administrative or regulatory action at this time. Consequently, the inspection is now officially closed, removing a significant regulatory overhang for this manufacturing site.

Inspection conducted at the Sanand, Ahmedabad facility from May 06, 2026, to May 15, 2026.
Received the Establishment Inspection Report (EIR) on August 08, 2026.
USFDA classified the inspection status as Voluntary Action Indicated (VAI).
The inspection process for the facility now stands officially closed.
Emcure reported a TTM revenue of Rs 9204 Cr, making regulatory compliance at major facilities critical for maintaining growth.

💡 Investors should monitor for any new Abbreviated New Drug Application (ANDA) approvals or product launches originating from the Sanand facility, as the VAI status typically allows for such approvals to proceed.

Emcure schedules 5 institutional investor conferences between August 12 and September 22, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Aug 2026, 07:37 PM

Emcure Pharmaceuticals has announced its participation in five major investor conferences over the next six weeks, starting August 12, 2026. These include high-profile events hosted by Emkay, Motilal Oswal, Elara, Kotak, and J.P. Morgan. The company, which currently holds a market cap of Rs 38,195 Cr and reported a TTM revenue of Rs 9,204 Cr, will engage in both group and one-on-one meetings. Management has clarified that no unpublished price-sensitive information (UPSI) will be disclosed during these sessions.

Participation in 5 distinct institutional investor conferences scheduled over a 41-day period.
First meeting is the Emkay 'Confluence 2026' on August 12, 2026, in Mumbai.
Final scheduled event is the 11th Annual J.P. Morgan India Conference on September 22, 2026.
Company maintains a strong financial profile with TTM PAT of Rs 941 Cr and ROCE of 24.0%.
Meetings involve major domestic and international brokerage houses including Kotak and J.P. Morgan.

💡 Investors should monitor the company's website or exchange filings for any investor presentations or transcripts released following these conferences to understand management's outlook on the Sanofi portfolio integration.

Emcure Schedules 5 Institutional Investor Conferences through September 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Aug 2026, 07:32 PM

Emcure Pharmaceuticals has disclosed its participation in five major institutional investor conferences scheduled between August 12 and September 22, 2026. The company will engage with analysts and investors at events hosted by Emkay, Motilal Oswal, Elara, Kotak, and J.P. Morgan. These meetings follow a strong FY26 performance where the company reported a TTM revenue of ₹9,204 Cr and a PAT of ₹941 Cr. No unpublished price-sensitive information is expected to be shared during these sessions.

Participation in 5 distinct investor conferences scheduled over a 41-day period.
First meeting at Emkay 'Confluence 2026' in Mumbai on August 12, 2026.
Final scheduled event is the 11th Annual J.P. Morgan India Conference on September 22, 2026.
Company maintains a TTM revenue of ₹9,204 Cr and an operating profit margin of 20.3%.
Promoter holding remains high at 77.8% as of the latest June 2026 filing.

💡 Investors should watch for any investor presentations or transcripts released on the exchange following these conferences for updates on the 14-15% growth guidance and the scaling of the Sanofi portfolio.

Emcure Pharmaceuticals schedules 5 institutional investor conferences through September 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Aug 2026, 07:24 PM

Emcure Pharmaceuticals has announced its participation in five major investor conferences between August 12 and September 22, 2026. The company will engage with institutional investors through group and one-on-one meetings hosted by Emkay, Motilal Oswal, Elara, Kotak, and J.P. Morgan. These interactions are part of routine investor relations, and the company has stated that no unpublished price sensitive information (UPSI) will be shared. This outreach follows a strong FY26 performance with TTM revenue of ₹9,204 Cr and a PAT of ₹941 Cr.

Participation in 5 distinct investor conferences scheduled over a 42-day period.
First engagement starts on August 12, 2026, at the Emkay 'Confluence 2026' Conference in Mumbai.
Final scheduled engagement is the 11th Annual J.P. Morgan India Conference on September 22, 2026.
Meetings will include both group and one-on-one formats with institutional investors.
Company maintains a TTM revenue base of ₹9,204 Cr and a market cap of ₹38,195 Cr.

💡 Investors should watch for any investor presentations or transcripts filed after these conferences for qualitative updates on the company's 5-year 'good to great' transition plan and chronic therapy expansion.

View All EMCURE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 18.6% YoY to INR 7,896 Cr in FY25. Domestic revenue grew 16.4% YoY to INR 3,660 Cr, while International revenue rose 20.5% YoY to INR 4,236 Cr. In Q2 FY26, total revenue reached INR 2,270 Cr, a 13.4% YoY increase, with the domestic business growing 10.6% to INR 1,031 Cr.

Geographic Revenue Split

In FY25, the domestic market contributed 47% of total revenue, while international markets accounted for 54%. Within international markets for Q2 FY26, Europe grew 22.7% YoY to INR 444 Cr, Canada grew 17.5% YoY to INR 348 Cr, and Emerging Markets grew 8.6% YoY to INR 446 Cr.

Profitability Margins

Gross Profit for FY25 was INR 4,749.4 Cr (60.1% margin), up 13.5% YoY. PAT grew 34.1% YoY to INR 707.5 Cr in FY25, with PAT margins improving 250 bps to 9.0% from 7.9% in FY24. Q2 FY26 PAT was INR 251 Cr, a 24% YoY increase.

EBITDA Margin

EBITDA margin stood at 18.6% for FY25 (INR 1,468.9 Cr), up from 18.5% in FY24. Margins expanded to 19.3% in Q2 FY26 and 19.84% in Q1 FY26, driven by operating leverage, productivity gains, and a shift toward chronic therapies.

Capital Expenditure

The company has planned an annual capex of INR 350-400 Cr for FY26 to support operational maintenance and capacity expansion. Additionally, it spent INR 725 Cr in FY26 to acquire the remaining 20.42% stake in its subsidiary, Zuventus Healthcare Ltd.

Credit Rating & Borrowing

CRISIL reaffirmed 'CRISIL AA-/Positive/A1+' and CARE assigned 'CARE AA-; Positive'. Interest coverage improved significantly to 9.03x in FY25 from 5.4x in FY24 due to debt reduction. Interest cost for Q2 FY26 was INR 33 Cr.

⚙️ Operational Drivers

Raw Materials

The documents mention APIs (Active Pharmaceutical Ingredients) and formulations as core components, but specific chemical names and their percentage of total cost are not disclosed.

Capacity Expansion

Planned capex of INR 350-400 Cr for FY26 is dedicated to capacity expansion and maintenance. Current installed capacity in units or MT is not specified.

Raw Material Costs

Gross margins stood at 60.8% in Q2 FY26, implying raw material and direct production costs are approximately 39.2% of revenue. Procurement strategies include in-house manufacturing for complex injectables to control the supply chain.

Manufacturing Efficiency

Efficiency is being driven by improved Medical Representative (MR) productivity and better utilization of in-house manufacturing for complex injectables and biosimilars.

📈 Strategic Growth

Expected Growth Rate

14-15%

Growth Strategy

Growth will be achieved through a 5-year plan focusing on 'good to great' transition, including strategic in-licensing (e.g., Sanofi portfolio), expanding the chronic therapy mix, scaling complex injectables and biosimilars in emerging markets, and accretive M&A such as the Mantra Pharma and Zuventus acquisitions.

Products & Services

Pharmaceutical formulations, biologics, APIs, complex injectables, biosimilars, and consumer wellness products.

Brand Portfolio

Arth, Galact, Mantra, Zuventus, and Sanofi (in-licensed products).

New Products/Services

Entry into consumer wellness via Arth and Galact brands; launch of in-licensed Sanofi products across various segments; and a pipeline of complex injectables and biosimilars.

Market Expansion

Expansion into the consumer wellness space and scaling up the international business, particularly in Canada, Europe, and Emerging Markets through differentiated products.

Market Share & Ranking

Emcure is a top 15 pharmaceutical company in India with a domestic market share of 2.18% as of March 2025.

Strategic Alliances

Strategic in-licensing arrangement with Sanofi to promote and distribute their products in India; partnership with Mantra Pharma Inc. in Canada.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and complex generics. Emcure is positioning itself by increasing its chronic portfolio and investing in biosimilars to outpace industry growth.

Competitive Landscape

Operates in a highly competitive environment against both domestic and international generic players, facing constant pricing pressure.

Competitive Moat

Moat is built on a top 15 domestic ranking, a 2.18% market share, and a differentiated product pipeline. Sustainability is supported by high entry barriers in complex injectables and long-term MNC in-licensing partnerships.

Macro Economic Sensitivity

Sensitive to government healthcare policies and DPCO pricing regulations in India, which directly affect revenue from the domestic formulations market.

Consumer Behavior

Increasing demand for chronic disease management and consumer wellness products is driving the company's shift in therapy mix.

Geopolitical Risks

Minimal exposure to the US market (safeguarding from US tariff risks), but faces regulatory risks in other regulated markets like Europe and Canada.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Drug Price Control Order (DPCO) in India and stringent manufacturing standards/safety protocols globally. Compliance is critical to avoid product withdrawals or regulatory actions.

Environmental Compliance

The company maintains a health and safety policy to comply with legislative requirements and certifications, though specific ESG costs in INR were not disclosed.

Taxation Policy Impact

The effective tax rate was 26% for Q2 FY26.

Legal Contingencies

Resolution of HDT and anti-trust lawsuits in 2024 has reduced uncertainty; however, the company remains exposed to ongoing legal and regulatory risks inherent in the regulated generics business.

⚠️ Risk Analysis

Key Uncertainties

Potential for sizeable debt-funded acquisitions to alter debt protection metrics; regulatory changes in international markets could impact 54% of revenue.